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T he specifi c detection of tUl11 0 rs in vivo using a radiola-
beled syngeneic mo nocl o nal antibod y made by fu sion o f 
P3U1 (BALB/c m yelo m a cell s) and C57B Ll6 spleen cell s 
p rim ed with syngeneic B 16 melano m a cells was inves ti-
ga ted by colo r imaging , auto radiog raph y, and biodistri-
b ution. The radio labeled anti melano m a antibod y specifi-
ca lly accumulated o nly in the tumor lesions, whereas no 
radi oactivity was o bse rved in no rmal tissues or o rgans. The 
dis tributio n patterns of the radioactive antibod y in the tu-
mor lesions depended o n the sizes of the tumo r. Alm os t 
th e entire regio n o f the sm all m etas tatic tum o r in lymph 
nodes was labeled , whereas the radioactive antibod y w as 
T he develo pment of m o no clo nal antibo d y techno logy enabled us to use specific antitumo r antibodies as di-agnosti c o r th erapeuti c agents fo r ca ncer. The use o f cyto to xic drugs, to xin s, o r radi oiso to pes co upled to . m onoclonal antitum o r antibodies m ay be ideal to spe-
clficall y kill tum o r cells [I-5 1. A prerequisite fo r pass ive im-
m unotherapy, however, is that th e antibodi es are able to reach 
target tum o r cells in vi vo w ithout deg rad ation o r rem ova l of the 
antibod y activity. In this sense, the murin e sy ngeneic m o noclo nal 
an timel ano m a antibody (M 2590), recentl y es tablished in our lab-
o ra to ry by the fu sio n ofBALB/c m yelo ma (P3 Ul ) and C 57BLl6 
sp leen cells primed w ith syngeneic B 16 melan o m a cells, has ideal 
cha racte ristics fo r applica tion o f di agnos ti c and th erapeutic mea ns. 
The antibod y reacts w ith bo th hum an and m ouse melano ma an-
tigens on the cell surface [6] and detects th e anti gens in th e tum o r 
tissues , but not in the sera o f patients o r animals w ith mel ano m as 
[7] , and also shows no reactiv ity to no rmal tiss ues and o rgans 
[6,8]. Therefore, the m onocl onal antibod y is ex pected to give 
higher tumor uptake with less clea rance from the circul ati on . 
T he location of animal and hum an tum o rs in vivo has been 
dem onstrated by use of radiolabeled monoclonal antibodies [9-1 4J. 
Som e radiolabeled mouse m o nocl onal antibodies against human 
tu m or cells have been shown to exhibit high backg round acti vity 
in the imaging of the human tum o r that obscures th e loca tion o f 
tumor lesions if the subtraction mcthods were no t applied. How-
ever, syngeneic m onoclonal antimelano m a antibodies w ithout de-
Manuscript received October 20, 1986; accepted fo r pu blication J anuary 
8, 1987. 
T his work was supported in part by grants from the Ministry of Ed-
ucation, C ulture and Science, and from the Minis try of Wel fa re, Japan. 
Reprint reques ts to: Masa ru T an iguchi, M.D ., Department o f Im-
m u nology, School o f Medicine, Chiba Un iversity, 1-8-1 Inohana, C hiba. 
Japan 280. 
irregularl y locali zed m ainl y in the center o f the m edium-
sized tumor. However, onl y the peripheral region o f the 
large primary tumor w as labeled. The hig hes t uptake o f 
radioactivity (tumor:blood ratio) w as o bserved in the small 
lymph node metastati c tumo r lesions rather than in the 
large primary tum o r. Furthermore, hig h resolution color 
imaging of B1 6 melano ma was also obtained by using 1251_ 
labeled m onoclo nal antibody. Tumor loca tion w as specif-
icall y vi sible w ithout subtraction o r enhancem ent methods 
3-5 days after injectio n o f the radio labeled antibod y. ) 11/-
/J est Denl/ato/ 89:225-229, 1987 
tectable reacti vity to no rm al tissues would provide idea l tools fo r 
specifi c detecti on o f th e loca ti on of tum o rs in vivo. M o reover, 
the use of the mo noclo nal antibody with interspecies reacti vity 
is idea l fo r es tablishing anim al models fo r the diagnosis o f hum an 
melano m as in vivo. . 
In this repo rt , we describe the tum o r loca tion of the syngcncic 
m onocl onal anti melan o m a antibody (M 2590) . The rcs ults sho w 
excell ent detection of melano m as by extern al pho toscann ing w ith 
display of radioacti v ity data as a colo r-sca led image or auto ra-
diograph y in the ex perim cntal anim al m odel. 
MATERIALS AND M ETH O DS 
Mice C57B Ll6 C rSlc mice, 8-1 2 weeks o ld , were purchased 
fro m the Shizuo ka E x perim ental Anim al Labo ratory Co . , Ltd., 
H am amatsu , J apan . 
Tumor Cell Line C57B Ll6 deri ved B1 6 m elano m a cell line 
11 5] was used . 
Monoclonal Antibody M o use syngeneic m onoclo nal anti-
melano m a antibod y (M 2590: lg M) w as esta blishcd b y the fu sion 
o f BALB/c m yelo ma (P3 Ul) with C57BLl6 spleen cells repcat-
edl y immunized with syngeneic B1 6 m elano m a cells [6]. Pro p-
erti es and charac teristi cs of the monoclonal antibod y (M 2590) 
have been described else where [6,8]. The antibod y reactcd w ith 
melano m a cells o f m o use, hum an, and hamster o ri g in , but no t 
w ith no rm al tissues o f C 57B Ll6 micc so fa r tes ted, including eye, 
skin , and brain , no r w ith o ther mouse tum o r cells, including 
neuroectoderm al tum ors, such as ncuro blasto m as. The interspe-
cics determin ants detected b y the M2590 antibo d y w ere found to 
be G M 3(N euA c) gangliosidcs [1 61. Aff1l1ity (kD) of M 2590 to 
G M3 gang li os ide w as 1 J.Lg / ml as enum erated by scatchard anal-
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Iodination Conju gation of monoclonal antibody w ith iodinc-
125 was ca rri cd out by thc iodogcn method of Salacinski and 
colleagues 117]. The reaction mixture was passed through a Seph-
adex G-25 colullln for sepa ration of free radioiodinc. Specific 
activity used in this study was 2-4 /-LC i/ /-Lg protein. I.ml11un o-
reactivity of thc labeled antibody was generall y 12 to 1/3 of original 
antibody activity as tcsted in cell':'binding assay . 
Organ Distribution ofIsotope-Labeled Immunoglobulin in 
Tumor-Bearing Mice B16 melanoma-bearing mice rcceived 
i. v. 1251-labeled monoclonal antibody (M2590) or 1251-labeled con-
trol m yeloma protcin (CBPC-112:lgM) witho ut specifi c binding 
activity (50 /-LCi). Generall y, drinking wa ter was supplemented 
with 0. 1 % Lugol's iodine throughout the experim ents. Five da ys 
later, the mice were killed and dissected. Tumors, visceral organs, 
eye, brain, thyroid, skin , and blood sa mples were weighed and 
assayed for radioactivity. Results were expressed as a percentage 
of inj ected radioactivity per gra m tissue (% dose /g) and as the 
organ:blood ratio of radioacti vity. Finall y, the specificity index 
of organ location was calculated by dividing the specific antibody 
uptake into the organ by the contro l m yeloma protein uptake 
according to the following formu la: 
S ·fi· . d (organ: blood ratio)M2590 peci IClty 111 ex = (organ :blood ratio)CBPC-112 
Scintigraphy and Autoradiography B16 melano ma cells (1 
x 106) were inoculated s.c. into the lower back ofC57BLl6mice. 
Mice were injected i. v. through th e tail vein w ith 50 /-LCi of 1251_ 
labeled monoclonal antibody or 1251-labeled myeloma protein 
(CBPC-112) (sp act 4 /-LC i/ /-Lg) . Six days later, the accu mul ation 
o f radioacti ve an tibodies was investigated by scinti graphy as de-
scribed elsewhere [9]. In ano ther experimelit, the technique of 
w hole-body autoradiograph y was used to stud y the distribution 
of radioactive monoclonal antibodies in sections of the tumor-
bea rin g mice [18] . Seven days after the antibody inj ection , the 
mice we·re sacrificed, freeze-dried , and cut into 40 /-Lm-thick sli ces 
with an autocryotome (NA 200F, N akagawa-Seikado, Tokyo). 
Sections were air-dried for 24-48 h at 4°C and then exposed to 
Fuji x-ray film (Fuji Industrial Photo Film Co., Ltd., Tokyo) at 
room temperature for 2-4 weeks in li ght- tight boxes. 
External Color Imaging N o rm al and melanoma-bearing mi ce 
in groups of 3 were given an i. v. inj ection of 50 /-LCi of the 1151_ 
labeled monoclonal antimelano ma antibody (sp act 4 /-LC i/ ug). In 
this experim ent, mice were given Lugol' s iodine in drinking water 
Table I. Organ Distribution of Radioiodinated Monoclonal 
Antibody in Melanoma-Bearing Mi ce" 
Contro l 
Antibod y 
Ant illlelanollla Antibody (CBPC-
(M2590) 11 2) 
Specificity 
O rgan % Dose/g Organ/I3Iood o,{, Dose/g Index 
Tumor 5.23 ± 0.62 3.35 1.03±0. 19 4.4 
Blood 1.56 ± 0.65 1. 00 1.34 ± 0.28 1. 0 
Brain 0.30 ± 0.05 0. 19 0.30 ± 0.06 0.9 
Retina 0.5 1 ± 0.07 0.33 0.56 ± O.OS 0.8 
Thyroid 1. 06 ± 0. 15 0.68 1.14 ± 0.38 0.8 
Heart 0.96 ± 0.18 0.62 0.79 ± 0.23 1. 1 
Lun g 1. 61 ± 0. 16 1. 03 1.46 ± 0.40 0.9 
Liver 1.89 ± 0.23 1.2 1 1. 92 ± 0.22 0.8 
Spleen 1.40 ± 0.3 1 0.90 1. 01 ± 0. 10 1. 2 
Kidney 1.87 ± 0.50 1. 20 1.47 ± 0.48 1.1 
Sk in 0.95 ± 0. 13 0.6 1 0.80 ± 0.28 1.0 
'C57BL/ti mice (4 mi ce) bea ring 131(, melano m a (20 X 30 mm) were injected 
w ith 50 !LC i of125I-labclcd anti m e\anoma (M2590) o r w ith 50 !LCi I'; I-Iabcled co nt ro l 
m yelo ma protei n (CBPC- 11 2). Results were show n as perce nt o finiria l radioactivity 
per g ram of o rgan (m ea n :t SD o f 4 sa mples) and as organ/ blood rali o. Specificity 
index = (orga n/ b lood ratio) M2S90/(organ/ bl ood rat io) CB PC -11 2. 
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Table II. Accumul ation of Monoclonal Antibody Depending 
on Size of T umor 
Tumor Size (nl1112) 
I x 2 
20 x 30 
30 x 50 
12SI-A ntibody Uptake 




"A C 57BL/6 m o use bearin g l3 16 mel all o m a W:l S injected wi th 50 .uCi of 1251_ 
labeled m o noclonal 311tibody (M2S90). The m ouse \vas the sa ml' as shown in Fig 
2. Another cxperim clH gave similar results. The data of o ne experimellt were shown 
here. TUlllo r/blood ratio = (% dose/g) tumor/ (% dose/g) b lood. 
sta rting 3 days before administration of radioactive agents . To 
avoid movement artifacts, anim als were anes th etized w ith sodium 
pentobarbital (50 m g/ kg i. p . injection) prior to imaging. The mice 
were scanned sequentially for 7 days w ith a scintillat ion camera 
(O hio Nuclear Sigma 410S, Technicare, Solon , Ohio) interfaced 
to a computer (V IP450 Com puter System, Technicare). 
RESULTS 
Biodistribution of 125I_Labeled Monoclonal Antibody in 
Melanoma-Bearing Mice The organ distribution of radioac-
tivity in n"lice bearing syngeneic B 16 melanoma was in vestigated 
by i. v . inj ection with 50 /-L C i of 12sl_labeled syngeneic monoclonal 
anti melanoma antibod y or an equal amount of 1251_labelcd control 
myeloma protein (CBPC-112:l gM) (Table I). Five days after rhe 
injection of antibody into mice bea ring medium-sized tumor (about 
20 x 30 mm), the radioactivity of M 2590 antibody, expressed 
as a percent dose/ g tissue, was significantl y grea ter in tumors 
(5.23%) than in health y o rga ns (0 .30-1. 89%) . The differences in 
the radioactivity of tum ors and no rmal tissues are sufficiently 
hi gh to achi eve statisti ca l significance (p < 0.01). The control 
m yeloma protein (CB PC-112) , however, could not show sig-
nifi cant differences between tum ors (1.03%) and health y organ 
(0 .3-1. 92%). The specifi city index of tum ors derived from the 
organ:blood ratio of the M2590 antibody was 4.4 when compared 
wi th the control myeloma protein, indica ting preferential uptake 
of the M2590 antibody into melanoma. The accumulation of 
radioactive monoclonal antibody (M2590) into the tumo r, how-
ever, was found to depend on th e tumor size (Table II). The 
highest ratio of uptake of radioactivity (20.7) was observed in the 
small metastatic tum or lesions (about 1 x 2 mm) in regional 
lymph nodes, w hereas the ratio of uptake detected in the large 
primary tumor (a bout 30 x 50 mm) was rather lo w (1. 2- 3.4). 
Tumor Location With 125I-Labeled Monoclonal Antime-
lanoma T um o r locati on by the radiolabeled antimelanoma an-
tibody was attempted w ith scintigraphy and autoradiography. 
Mice bearing B 16 mel anoma in the lo wer back were given 50 
/-LCi of 1251-labeled Jntimelanoma o r 1251-labeled control m yeloma 
protein (CB PC-112) 6 days previously. Scintigraphy showed sig-
nificant locali zation of radioactivity in th e region of the melanoma 
tumor (Fig l A). On the o ther hand , the radioactivity was nor 
detected in the area correspondin g to the tumor w hen the radio-
active control m yeloma protein was used (Fig 1B). It is thu 
demonstrated that the accumulation of radioactivity in the tumor 
entirely depends on the antibody specifi city. Nonspecific accu-
mulat io n of radioactivity was observed in the upper part of mice. 
This is due to the uptake of radioactive free iodine in the thyroid 
in this particular experimen t. 
The same mice as those used in the scannin g experim ent were 
sacri ficed and exa mined for tumor location of radioactive mono-
clonal antimelanoma by autoradiography. As sho wn in Fig IC 
and D , the radioactivity was localized onl y in the tumor region. 
T he radioacti ve antibody was irregularl y accu mu lated in the cen-
ter of the tumo r, however, w hen the tumor size was about 20 
X 30 mm . The radioactivity in the stomach was probably rhe 
result of metabolism of radioactive iodine (Fig ID). When the 
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Figure 1. Scintig ram and autoradiogram of melan o ma-bea ring mice. Th" sci migrams were o btained in C57 I3L16 mice bca ring 13 16 mclanoma (20 x 
30 mm in the ri ght lower o r back) 6 days previo usly injectcd w ith (A) ' ~' I - I abe lcd monoclonal anti melano ma (M 2590), o r (8) ' ~5 1-l abcled control 
myeloma protcin (Cn p -11 2). N o te that the accumu latio n of radioactivity in a ro und shape at the top of the scintigra m in (A) and (8) is due to the 
uptakc,_in the th yro id . The accumulation of the antimclanoma antibod y was furthcr in ves ti ga ted in hemisec tio n (e) o f mebno m a-bea rin g mice injected 
:"'lth '-' l-antimelanoma (M 2590) and corresponding auto rad iograph (D) showing irregul ar bu t central accumulation of the radioa cti ve M 2590 antibody 
In the tumor. Note that the rad ioacti ve area (ro und shape) of the middle left in (D) is not d ue to the mel ano ma, but to th e secretion of free iod ine in 
the stomach . Two other ex periments showed simi lar results. 
loca liza tion of the radioactive antibod y was in ves tiga ted in large 
tu mor lesions (about 30 x 50 mm), the antibod y preferenti all y 
accumul ated at the peripheral region but not in th e center o f the 
tumor (Fi g 2B). Moreover, 3 meta stati c tum or lesions in the 
regional lymph nodes (Fig 2B) were also visibl e, and almost their 
entire regions were labeled. 
Time Course of Gamma Camera Images in Normal and 
Tumor-Bearing Mice The feasibi li ty of co lo r imaging with 
time after inj ection of 1251-labeled monoclonal antibody (M2590) 
into normal and melanoma-bea rin g mi ce was studi ed. O ne hour 
after inj ection (Fi g 3A), the majo rity of radioacti vi ty was observed 
in the blood pool without organ-specifIC uptake of the radioactive 
antibody in both 11 0 rmal and tum or-bearin g mi ce. In tUIll Or-
bea rin g mi ce, howeve r, the radi oacti vity g raduall y accu mulated 
, . 
• ' r 
B 
with time in the tumor area, such as at 24 h (Fig 3B) , 3 days (Fig 
3C), and 5 da ys (Fig 3D) after th e antibody injecti on. In contras t, 
no rm al anima ls injected w ith th e sa me doses of 1251-antimelano ma 
antibody showed diffuse and nonspecifi c weak radioactivity. T he 
optimal time for tum or imaging was observed on day 5 after 
injecti on of the antibody. 
DISC USSION 
This stud y shows th at the radiolabe led m ouse monoclonal anti-
melano ma antibody w ith intcrspecies reacti vity to va ri ous human 
melanom as co uld effecti vely revea l the transplanted so li d mo use 
melanoma grown in syngeneic mice. The conditions o f the ex-
perim ental animal model in the present stud y reAect th ose of 
human patients w ith melanon1:1 ill terms of the treatm ent of hu-
Figure 2. Loca li za tion of rad ioactive 
mo noclonal antimcJano ma antibody 
(M 2590) in a m ouse bearing large-sized 
melanoma. A C57BLl6 mouse bearing 131 6 
melanoma (30 x 50 mm) was injected w ith 
,~s l -bbeled monoclo nal antimclano ma an-
tibody (M2S90) 7 da ys previously. Sectio n 
(A) of the melanoma-bea ring mouse was 
exa mined for accumulation of rad ioacti v-
ity by autoradiog raph y (8). N o te the lo-
ca li za tio n of rad ioactivity at the peripheral 
arca of th e tum o r and also in 3 metasta ti c 
tumor k sions in the regional lymph nodes. 
Another experiment gave simil ar results. 
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Figure 3. External colo r imaging w ith 1251-syngeneic m o no clo nal antime1a no m a (M 2590) antibod y in C57BLl6 mice wi th (right) o r w itho u t (lefi) B 16 
m elano m a. T he melano m a used in the experiments was approx imately 20 x 20 mm. T he im ages were ob tained at (A) 1 h , (B) 24 h , (C) 3 days, and 
(0) 5 days after the injectio n of [I25 IlM2590. The sam e mice were used thro ugho ut. T hree o ther ex periments yielded similar results . T he raw data are 
presented w ithout all Y backg ro und subtractio n. 
m·an m elano m a w ith sy ngeneic m onocl onal antitumor antibodies 
as in vivo diagnostic reagents. 
In fact, the present studies dem onstrated that the antibody was 
specificall y accumulated in the tum o r (T able I; Figs 1,2) . The 
tumo r locati on w as eas il y detected by the ex tern al imaging w ith 
th e syngeneic 12sI- labeled m onoclonal antibody (Fi g 3). T he com-
puterized blood pool o r norm al tissue subtraction technique was 
no t necessary to reveal the location o f tumo r. N onspecific ac-
cumul ation of radiolabeled antibod y was no t observed by auto-
radiograph y and ex ternal imagin g technique (Figs 2,3). 
The di stribution patterns of the radi olabelcd antibod y in the 
tum or lesions seem to depend on th e size o f th e tumo r. T he entire 
tum o r regions were strongly and rather ho m ogeneously labeled 
w hen they were sm all lymph node m etas tatic lesions (about 1 X 
2 mm) (Fi g 2). This was also repo rted by Epenetos et al [1 91 in 
human cases th at were given i. v. inj ection with radiolabelcd tu-
m or-associated m onoclonal antibodies, demonstrating that ly mph 
no de m etas tas is showed hi gher antibod y uptake th an their cor-
res pond ing primary tum o rs. The radio labeled antibod y, how-
ever, was irregul arl y loca li zed in the center o f the tum o r o f me-
diul11 size (about 20- 30 111m) (Fi g 1) and in the peripheral region 
o f the large-sized tUl11 0r (about 30 x 50 mm) (Fi g 2) . Two sm all 
nodules adj acent to th e large tum o r do not label (Fi g 28 ). It i 
possible these arc p:l rts of large tumors. In an y event, the local-
iza tion pattern s o f radioacti ve antibodies are quite irregular in 
tum o rs. 
It is likely th at the irregul ar di stributi on o f radioacti ve antibod y 
is a reRection o f an ex pression of M2590 determinants on mela-
no m a cells in va ri ous differenti atio n stages. In fac t, o ur recent 
experiment usin g two radioacti ve monoclonal antibodies, [' 25 IJM56_ 
and \' 3'l\M2590, either o f w hich recognizes different melanoma 
anti gen, cl earl y dem onstrated that the distribution patterns of 
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[125I]M562 and r131l]M2590 are quite distinct in the large tu mor; 
periphera l localization was obtained by M2590, w hereas central 
loca liza ti on was observed by the M562 antibod y. T hese res ults 
ca n.no t be acco un ted for simpl y by the vascul ar architecture in 
the tumor tissues. Similar findin gs on th e distribution of rad io-
acti vity has also been observed by others, such as Mos haki s et al 
[20] on malignant teratoma xenografts and Pimm et al 121 J on 
osteosa rco ma xenografts. 
Radioimmunoimag in g using the monoclonal antibodies reac-
tive aga inst hum an melanoma has been ca rried out by Murra y et 
al [22]. T hey used the antibody recognizing an M, 97,000 anti gen 
fo und on over 80% of melanoma cell lines and tissue extracts. 
Of a total of 100 previously documented metastatic sites, onl y 
50 were visible w ith imaging . Moreover, uptake of radioactive 
monoclonal antibodies was variable amon g metas tatic les ions in 
different organs. However, some metastases were revea led in 
patients receiving high doses o f radioactive antibod y. This sug-
gests that th e ex press ion of antigen on the surface varies in meta-
static lesions in var ious o rga ns. T he background tissues may affec t 
the differentiation of tumor cells so th at th e express ion of tum or 
antigens is va riable. T herefo re, .these restricted loca liza ti ons of 
monoclona l antitumor antibody w ill be of considerable impo r-
tance in the application of monoclonal antibodies fo r specifi c di-
agnosis and th era py. 
In our previous studi es [7], melano ma antigens fa il ed to be 
detected in the sera o f pati ents w ith melano ma, w hereas th e an-
tibody detected the anti gens in melanoma ti ssues from the sa me 
patient. T he anti geni c determinants detected by the M2590 an-
tibody were demonstrated to be composed of G M3 gang lioside 
[16] and the terminal sialic acid was cru cial for the ex pression of 
the antigeni city 18]. It is th erefore likely th at the circul at ing mel-
ano ma antigens lose their interspecies reacti ve dete rmin ants due 
to the action of sialidases in the tiss ue 1'23 L sugges tin g that the 
M2590 antibody injected into the tum or-bea rin g host should di-
rectl y reach the tUlll o r nest w ith out loss o f its antibody ac tivity. 
T hus, the antibody inj ected seems to beco me effectivel y loca li zed 
in the tUlll Or. 
The mouse monoclonal antibody used in this stud y recognizes 
the melanoma antigeni c determi nants w idely shared in va ri ous 
ma mmalian melanomas and reacts w ith hum an as we ll as mouse 
melanomas [6,8]. It is thus easy to speculate that human m ono-
clonal antibodi es recogni zing the interspecies reactive melanom a 
determinants, w hen they are estab li shed , w ill prove to effectively 
reveal human melano mas. 
REFERENCES 
1. Gilliland DG , Stcplewski Z , Co ller 1) , Mitchel l KF, C hang T H , 
Koprowski H : Antibody directed cyrotox ic agents: li se of mono-
clonal antibod y to direct the action to rox in A chains to colorec tal 
ca rcino m'l cells. Proc N at! Acad Sci U SA 77:4539-4543, 1980 
2. Hashimoto Y, Sugawa ra M , M as uko T, Hojo H: Anti-tum or effect 
of actimomycin D entrapped in Ii poso mes bea ring subunits o f 
tum or-specific monoclonal imlllunogiobulin M antibody. Cancer 
Res 43:5328-5334, 1983 
3. Kro lick KA , U hr J W, Slav in S, Vitetta ES: In v ivo therapy of a 
murine 13 cel l tum o r (BC LI ) usin g antibody- ri cin A chai n im-
munotoxins. ) Exp Med 155 :1 797- 1809, 1982 
4. M ew D, Wat CK, Towers G HN , Levy ) G: Photoimlllunotherapy: 
treatment of animal tum o rs wi th tum o r specific monoclona l an-
tibod y-hematoporph yrin conjugates. J Immunol 130: 1473- 1477, 
1983 
5. Thorpe PE, I3rolV n ANF, Ross wq, C umber AJ , Detre SI, Ed-
wards DC, Davies A) S, Stirpre F: Cytotox icity acq uired by con-
j uga tio n of an anti-Th y-I . I monoclonal antibody and the ribo-
so me-inacti vating prote in, Gelo nin. Eur J Biochem 11 6:447-454, 
198 1 
BIODETECTION O F MELANO MA 229 
6. Wakabayashi S, Saito T , Shinohara N , O kamoto S. Tomioka H , 
Tani guchi M: Syngeneic monoclonal antibodies aga inst melano ma 
antigens with species specifi city and intcrspecies cross-reactivity . 
) In vest Derm ato l 83 :1 28- 133, 1983 
7. Wakaba yashi S, Okamoto S, T an igllchi M: Sa ndw ich rad io immu-
noassay using sing le monoclona l antibody that detects minute 
amounts of melanoma antigens from va rious rn am malian species. 
Gann 75:427-432, 1984 
8. Taniguchi M , Wakabayashi S: Shared antigenic determinant ex-
pressed on va rious mam m'lli an melanoma cells. Gamm 75:418-426. 
1984 
9. Colcher D, Za lutsky M , Kaplan W, Kufc D, Austin F. Schlo m J: 
Ibd ioloca li za rion of hum an mammary tumors in ath ymic mice 
by a monoclona l antibody. Cancer Res 43:736-742, 1983 
'10. Mach)P, C hata l) F, LlI mbrosa )D, Buchegger F. Forn i M , Ritschard 
J: Bcrche C , Douillard )Y, Ca rrel S, Herl yn M , Steplewski Z, 
Kop rowski H: T um o r loca li za tion in patients by radio labeled 
mo noclona l .antibodies aga inst colo n ca rcinoma. Ca ncer Res 43: 
5593-5600. 1983 
11. Haske! CM, Buchegger F. Schreyer M, Ca rrel S. Mach)P: Mono-
clonal antibodies to ca rcinocmbrionic antigen: Ionic strength as a" 
facto r in the selection of antibodies for im lll unoscin tig raphy. Can-
cn Res 43:3857-3864, 1983 
12. Larson SM: Radiolabelcd mo noclonal anti-tumo r antibodies in di-
agnosis and therapy. ) Nucl Med 26:538-545, 1985 
13. l3 uchegger F. Mach ) P, Leonnard P, CarrCl S: Selecti ve tumor lo-
ca li za tion of radiolabcled anti-hum an melano ma monoclonal an-
tibody fragmcn t demonstrated in the nude mo use model. Cancer 
58:655-662, 1986 
'1 4. Delanoye 13, Bischof-Delaloye A, Buchegger F, von Flidner V, Grob 
)P, Volant ) C , Petta vel J , Mach )1': Detection of colorecta l car-
cino ma by emiss ion-co m puterized tomograph y after injection of 
12.11_labelcd Fab or F(ab 'h frag ments fro m monoclonal anti-ca ri -
cinoe mbryonic antigen antibodies.) C lin Inves t 77:30 1-311, 1986 
15. Hu I: , Lesney PF: The isolation and cy to logy of two pig ment cell 
strains from 13 16 mo use melano mas. Cancer Res 24: 1634- 1643, 
1964 
16. Hi yaba yashi Y, Hamaoka A, Matsumoto M , Matsubara T , Tagawa 
M , Wakaba yashi S, Taniguchi M: Syngeneic monoclonal anti body 
aga inst melan o ma antigen with in terspecies cross- reactivity rec-
ognizes G M3 • a prominent gang lios ide of 1316 meiano n1J . ) B.i o l 
C hel11 260: 13328-13333, 1985 
17. Sa lacinski PRP, Mclean C, Sykes ) EC. C lement-)o nes VV, Lowry 
PJ: Iod ination of proteins, glycoproteins, and pep tides using a 
so lid-phase ox idizin g agent, I ,3, 4,6-te trachloro-3,6-diphenyl gly-
coluril (Iodogen). An al Biochem 11 7: 136-1 46, 1981 
'1 8. Berg n1Jn K, Tja lve H : T hree-step autoradiograph y of o rga nic sol-
ven ts and pl ilsti c 111011 0 l11 ers to register tota l radioactivity. no n-
volatile metabo lites, and no n-ext ractable me tabo li tes. Acta Phar-
macol Toxicol (Copen h) 4 1 :22-23, 1977 
19. E penetos AA , Snook D, Durbin H , Johson PM , Taylor- Paradim i-
triou): Limitations of rad iolabeled monoclonal antibodies fo r lo-
ca lization of hum an neoplasms. Cancer Res 46:3183- 319 1, 1986 
20. Moshak is V, M cilhinney RAJ, N eville AM : Cellular dist ri bution o f 
lll onocional antibod y in human tU lllors after iv administration. Br 
J Cancer 44 :663-669, '1 981 
2 1. Pinlln M V, E mble ton M) , Perkins AC, Price MR , Robins RA, 
Robinson GR, Bald man RW: In vivo locali za tion of anti-osteo-
genic sa rcoma 791 T 1110noclon:li antibody in os teogenic sa rcoma 
xenografts. Int) Cancer 30:75-85, 1982 
22. Murray JL, Rosenblum MG, Sobol RE, Bartho lo mew RW , Plager 
CE, Haynie TP, Jahns MF, Glenn H) , Lamki L, Benjamin RS, 
Papadopoulos N , Boddie AW, Frincke )M , David GS, Carlo D) , 
Hersh EM: Radioiml11unoim aging in malignant melanoma w ith 
I I I In- labeled monoclonal antibody 96.5. Cancer Res 45:2376-2381, 
1985 
23. fl ab" T , Ishii M , Aoki K: Eleva tio n of li ve r neuraminidase acti vity 
in the tum o r-bearing hos t. A biochemi ca l approach to the mech-
anism of cancer invasion and metastasis formation. Gam m 55: 
331-339, 1964 
